🧠
Paradromics: Achieving a Milestone in Brain-Computer Interface Technology
Paradromics, a neurotechnology startup based in Austin, Texas, has successfully completed its first human implantation of the Connexus brain-computer interface (BCI), marking a significant advancement in the field.
🧪
First Human Implantation of Connexus BCI
• On May 14, 2025, during a scheduled epilepsy surgery at the University of Michigan, neurosurgeons temporarily implanted the Connexus device into a patient’s temporal lobe.
• The procedure lasted approximately 10 to 15 minutes, during which the device recorded neural activity, demonstrating its capability to capture meaningful brain signals.
💡
Advancements in Neural Signal Recording
• Connexus features a compact design—smaller than a dime—with 420 electrodes capable of high-resolution signal capture at the neuron level.
• This design aims to decode speech-related neural activity more precisely, potentially translating brain signals into speech, text, and cursor movements.
🔬
Transition to Clinical Trials
• Following this successful procedure, Paradromics plans to initiate long-term clinical trials by the end of 2025, pending FDA approval.
• The trials will focus on individuals with severe motor impairments, such as those resulting from ALS, stroke, or paralysis, aiming to restore communication abilities.
💰
Strategic Partnerships and Funding
• In February 2025, Paradromics announced a strategic investment from Saudi Arabia’s Neom, signaling growing international interest in BCI technology.
• To date, the company has raised nearly $100 million in funding, supporting its mission to develop high data-rate BCI systems.
🏁
Positioning in the BCI Landscape
• Paradromics’ recent achievement positions it as a notable competitor to other BCI developers, including Elon Musk’s Neuralink, which has also been conducting human trials.
• The successful human implantation of Connexus underscores Paradromics’ commitment to advancing neurotechnology and its potential to impact individuals with severe motor impairments.
As Paradromics moves forward with clinical trials, the company’s innovative approach to brain-computer interfaces holds promise for transforming the lives of individuals facing significant communication challenges.
📊
Powered by V3V Ventures